InMed Pharmaceuticals Amends Preferred Investment Options

This is a dilution event, not a growth catalyst—no cash raised, just cheaper warrants.

Risk flags

• ●Dilution risk is significant: if all 2,304,714 options (Sabby plus Wainwright) are exercised at $0.80, the share count will increase substantially, diluting existing shareholders. This matters because it reduces per-share value and future upside for current investors.
• ●No assurance of exercise: the company explicitly states that there is no guarantee any options will be exercised, meaning there is no certainty of new capital inflow. This leaves the company’s funding outlook highly uncertain.
• ●Lack of financial disclosure: the announcement omits any information about current cash position, burn rate, or recent financial results. Investors cannot assess whether the company is at risk of running out of cash or how urgent the need for new funding is.
• ●Lowering exercise prices signals weak demand: reducing the exercise price from as high as $82.50 to $0.80 suggests that prior terms were unattractive and that the company may be struggling to raise capital at higher valuations. This pattern is often a sign of financial distress or limited investor appetite.
• ●No operational or pipeline progress disclosed: the company makes generic claims about its pipeline and leadership in rare cannabinoids, but provides no data, milestones, or evidence of advancement. This raises questions about the underlying business momentum.
• ●High forward-looking content: most of the potential benefit is contingent on future actions by third parties (option holders), not on any realized event. This means the majority of the value proposition is speculative and unproven.
• ●Geographic and regulatory risk: as a British Columbia-based company operating in the pharmaceutical sector, InMed faces both Canadian and U.S. regulatory hurdles, but the announcement does not address any progress or challenges on this front.
• ●No institutional endorsement: while Sabby and Wainwright are named as option holders, there is no evidence of new institutional investment or endorsement—these are amendments to existing agreements, not new capital commitments.

Bottom line

For investors, this announcement is a technical adjustment to previously issued warrants, not a sign of new growth or operational progress. The company is making it cheaper for existing option holders to buy shares, but there is no evidence that any will do so, or that any cash will be raised as a result. The lack of financial disclosure—no cash balance, no burn rate, no revenue or expense data—means investors are flying blind on the company’s true financial health. The move to lower exercise prices so dramatically is a clear signal that the company was unable to attract capital at prior, higher valuations, which is a negative indicator for demand and perceived value. No new institutional investors are participating, and the only named individual is a communications executive, not a capital allocator. To change this assessment, the company would need to disclose actual option exercises, cash proceeds, or meaningful operational milestones. Investors should watch for any 8-K filings or press releases confirming the exercise of these options and the receipt of funds, as well as any updates on pipeline progress or financial results. Until then, this is a signal to monitor, not to act on: it is a dilution risk with no guaranteed upside. The single most important takeaway is that this is a defensive, not an offensive, move—InMed is lowering the bar for capital inflow, but there is no evidence yet that anyone is willing to step over it.

Announcement summary

InMed Pharmaceuticals Inc. (NASDAQ: INM), a pharmaceutical company based in British Columbia, announced it has entered into amending agreements regarding preferred investment options with Sabby Volatility Warrant Master Fund, Ltd. and certain affiliates of H.C. Wainwright & Co., LLC. The amendments reduce the exercise price for both Sabby and Wainwright Parties' preferred investment options to $0.80 per common share. Previously, Sabby had the right to purchase up to 2,151,478 common shares at $2.436 per share, and the Wainwright Parties could purchase up to 153,236 common shares at $82.50, $20.75, and $3.2013 per share. These options were offered in private placements. There is no assurance that any of the preferred investment options will be exercised.

Disagree with this article?